Background: With common over-the-counter (OTC) medication use, OTC labels as medicine information sources must be of high quality and usability. Standardized OTC labeling has been proposed in Australia using the Medicine Information Box (MIB), modeled on the US Drug Facts label. However, limited research has explored consumer opinions on existing nonstandardized Australian OTC, US Drug Facts, and proposed MIB labels. Therefore, this study aimed to explore consumer opinions on all 3 groups of OTC labels. Methods: Three focus groups (N ¼ 21 participants) were conducted in Sydney, Australia. Participants were shown existing Australian OTC labels, US Drug Facts labels, and mock MIB formats based on the Australian Therapeutic Goods Administration proposal. Discussions were audio recorded, transcribed verbatim, and thematically analyzed. Results: Participants expressed varying opinions regarding existing nonstandardized Australian OTC labels' content and design, from acknowledgment of positive aspects (clear headings, relevant content) to decreased perceived readability (suboptimal color use, font size) and content discrepancies. Participants identified key Drug Facts and MIB label characteristics that contributed to perceived usability and format clarity (good headings, black-and-white format). Many preferred the Drug Facts label because of its greater perceived clarity and usability. Missing content (inactive ingredients, further contact details) were identified and consequently became opportunities for MIB improvement. Conclusions: Most participants seemed to prefer the US Drug Facts label, partly because of its perceived completeness. These findings suggest further improvements for the proposed MIB as a step toward Australian OTC label standardization.
Introduction
Consumer use of over-the-counter (OTC) medicines is common, 1 and the availability and provision of relevant, highquality OTC medicine information is therefore necessary to assist consumers with safe medication use. Consumers want information on the effectiveness of the medicine, dosing, potential side effects, and possible drug interactions prior to taking an OTC medicine 2 and will read OTC labels to obtain such information. 3 As consumers recall only a proportion of spoken information provided by pharmacists, 4 written medicine information sources are critical.
Design and comprehensibility of written OTC medicine information contribute to their quality. 5 Consequently, efforts to improve the usability of OTC labels and leaflets are imperative in supporting medication safety. For example, standardization of OTC labeling in the United States (US) using the Drug Facts label format 6 was implemented to ensure format consistency and increase usability. Consumers who utilized the Drug Facts label gave statistically significantly more correct responses on the whole, in relation to the appropriate action required to be taken in four different scenarios relevant to warnings information, than when using the older label format. 7 Furthermore, consumer preference ratings for the Drug Facts label for a pain reliever were statistically significantly higher than for the corresponding older label format. 7 Other studies have also noted an improved time taken to find information when using the Drug Facts label compared to older label formats. 8, 9 In contrast to the United States, OTC labels are not standardized in Australia. 10 Despite this, standardization of written medicine information in Australia is not unknown, as leaflets known as Consumer Medicine Information are available in a standardized format and are mandatory for both prescription and pharmacist only OTC medicines. 11 In Australia, existing legislation 12 provides a comprehensive outline of the label content required. 13 However, with labeling, consumers face a number of potential problems such as impaired label readability (because of factors such as small font size and amount of content), difficulty in understanding and acting upon relevant medicine information, in addition to relating the information back to their own personal needs. 14 A 2012 consultation paper published by the Australian Therapeutic Goods Administration (TGA) implied the need to improve OTC labeling, proposing the introduction of a standardized OTC label format titled the Medicine Information Box (MIB), modeled on the US Drug Facts label format. 15 Limited research has explored consumer opinions on the MIB in Australia. Furthermore, opinions on existing labeling standardization, namely, the US Drug Facts label, have not been explored in a consumer population such as Australia, where regulatory activities indicate that OTC label standardization may be implemented in the near future. As the MIB is based on the Drug Facts label format, 15 it is prudent to explore consumer opinions on both formats for comparison prior to the implementation of standardization. Therefore, the study aim was to explore consumers' opinions on existing Australian nonstandardized OTC labels, the US Drug Facts label, and the MIB.
Methods
This study formed part of a larger international research project exploring consumer OTC medicine information needs and use, and perspectives on OTC medicine information. The study received ethics approval from the University of Sydney Human Research Ethics Committee (project number 2013/1013). Participants provided written informed consent to participate in this study.
Participants and Setting
Three focus groups lasting approximately 1 to 1.5 hours were conducted in Sydney, Australia, in February 2014 with a total of 21 participants (Table 1) . Focus groups were utilized to address the study aim, and complement a series of earlier semistructured interviews that explored consumer perspectives on the MIB specifically. 16 The group dynamic inherent in focus groups was intended to encourage discussion about, and comparison between, all 3 label types.
Each focus group was conducted by 2 experienced female focus group facilitators (P.A., K.K.H.), with field notes taken by 2 researchers (N.P., B.A.). People were eligible to participate if they were aged 18 years and older, conversant in English (did not require a translator to participate in the study), and had purchased an OTC medicine in the 6 months prior to the study for personal use or for an individual under their care. All participants were identified from the consumer database of a market research company using the inclusion criteria specified. Potential participants were contacted and provided with an information sheet and consent form, and if willing to participate, were assigned to attend one of the scheduled focus groups held at various venues in Sydney. Participants were reimbursed AU$80 for their time.
Focus Group Protocol
The focus group protocol was developed to address the broader research project aims, and included specific questions regarding consumers' OTC medicine information needs, utilization of OTC medicine information, and perspectives on existing and proposed OTC labeling strategies (Australia and United States). Only findings pertaining to the study aim described here will be presented.
During the focus groups, participants were shown 3 broad groups of stimulus materials in the following order: Table 2) ; and 3. 2 mock MIB labels for exemplar study medicines diclofenac and pholcodine (developed and published previously, 16 based on the TGA consultation paper 15 ) ( Figure 1 ).
Participants were asked to review the stimulus materials provided, and participant opinions on the different labels were sought. Table 3 provides the broad, core questions included in the semistructured focus group protocol, utilized by the facilitators to help stimulate discussions.
Labels on existing products were presented as they would be available at the point of purchase, with no changes in packaging or removal of leaflets (where available). They were randomly chosen and purchased from a pharmacy in Australia and the United States to represent a range of dosage forms, potential user demographics, and labeling characteristics/conditions (for instance, total packaging size). The US products allowed participants to visualize actual OTC label standardization and its impact on overall OTC packaging.
Both MIB labels were given to the participants as paper copies, not contextualized as part of complete OTC product packaging.
Data Analysis
Thematic saturation 17 was achieved with the 3 focus groups conducted. All focus groups were audio recorded with permission from the participants and were transcribed verbatim. Transcript accuracy was verified by checking transcripts against the relevant original audio recording prior to analysis. Checked transcripts were analyzed via thematic content analysis. 18 Three researchers (V.T., B.A., and N.P.) independently analyzed the data, and themes were verified in consultation with another researcher (P.A.). Preliminary data analysis was conducted by hand on the checked transcripts. Subthemes were determined from the data, and refined and conceptually grouped under identified broad themes. One researcher (V.T.) presented the data using a matrix display, 19 which was compared with the themes and subthemes identified by the other 2 researchers.
Results

Consumer Perspectives on Existing Australian OTC labels
Positive label characteristics Some participants appreciated the clear headings and large font size of the writing on a proportion of existing Australian OTC labels examined. The simple wording and color used on the Nurofen label were perceived positively and were believed to increase readability (see Table 4 , quote 1).
Barriers contributing to perceived information retrieval difficulty
Participants noted numerous label characteristics that contributed to information retrieval difficulties. A mixed portrait and landscape headings arrangement adopted by the Codral 4 Flu label was perceived to contribute to increased time needed to read the information, in comparison to the simpler Gastro-Stop label (2-column landscape format) ( Table 4 , quote 2). Small font size was an issue mentioned in every focus group. Decreased font size increased perceived consumer difficulty in reading information, but this appeared to be less if the participant thought they had good eyesight. Specifically, small font size proved problematic with the Panadol suppositories label (most label text printed in font 1 mm high), potentially contributing to self-selection errors as the dosage form was not immediately apparent ( Table 4 , quote 3).
Color had varying impact on readability, where the red-andorange Nurofen label was seen as more difficult to read than a label that utilized higher contrasting colors ( Table 4 , quote 4). This was in contrast to an earlier comment made by participant FG2 F3 (Table 4 , quote 1).
Label content: Perceptions and identified discrepancies
Overall, many thought existing Australian OTC labels included relevant key information relating to product use (such as
Medicine InformaƟon Box AcƟve Ingredient
Each tablet contains: diclofenac potassium 25mg
Uses Short term relief of pain and swelling related to migraines, back, joints, period pain, or sprains/strains.
Warnings and Allergy InformaƟon
Do not take Diclofen if you have:
• A stomach ulcer or other stomach problems • Heart failure • Kidney problems • Allergies to any of the ingredients in Diclofen, or other anƟ-inflammatory medicines like aspirin Do not take Diclofen if you are pregnant. Do not give Diclofen to children less than 14 years old. Please read the Medicine InformaƟon Leaflet inside the pack before using Diclofen.
When using this product
Do not take Diclofen:
• Together with other anƟ-inflammatory medicines, including other medicines that also contain diclofenac • For more than a few days at a Ɵme, unless advised by your doctor You may experience common side effects like: nausea, stomach upset and dizziness. Be careful if driving or operaƟng machines unƟl you know how Diclofen affects you. Talk to your doctor or pharmacist if your symptoms get worse or do not get beƩer.
DirecƟons
Adults and children older than 14 years old Take 2 tablets at first, Then take 1-2 tablets every 8 hours if needed.
Do not take more than 8 tablets in 24 hours.
Storage informaƟon
Store tablets in a cool, dry place at room temperature (below 30°C).
Medicine InformaƟon Box AcƟve Ingredient
Every 5mL of Benpholc contains: 5mg pholcodine
Uses
Helps relieve a dry cough in the short term in adults and children more than 6 years old
Warnings and Allergy InformaƟon
Do not use Benpholc if you or the person you are giving it to:
• Is a child less than 6 years old • Has breathing problems • Has an allergy to any ingredients in Benpholc • Has a wet cough Speak to a doctor, pharmacist or nurse before giving Benpholc to a child between 6 and 12 years old. Please read the Medicine InformaƟon Leaflet inside the pack before using Benpholc.
When using this product
• Benpholc may make you or your child drowsy Take care when driving or using machines if you are an adult • Avoid drinking alcohol whilst taking Benpholc Speak to your doctor or pharmacist:
• If the cough worsens, changes or does not get beƩer • Before using/giving any other cough and cold medicines together with Benpholc
DirecƟons
Age How much How oŌen 6-12 years 2.5-5mL 3 to 4 Ɵmes a day Adult 10-15 mL Do not give or take more than 4 doses of Benpholc in 24 hours. Do not give Benpholc to a child for longer than 5 days unless your doctor has advised you to.
Storage informaƟon
Store Benpholc in a cool, dry place at room temperature (below 30°C). Keep out of reach of children. directions and warnings), raised in every focus group. Despite this, the notion of content discrepancies was also discussed in every focus group, where some identified content discrepancies between different OTC products, and/or between the label and corresponding leaflet for a single product such as the Daktarin cream. For instance, contact details such as a website and/or telephone number were identified as missing from some labels. In particular, the potential safety implication for inconsistent inclusion of emergency contact information between the label and corresponding leaflet was implied by one participant ( 
Diclofenac MIB Pholcodine MIB
Suggestions for label design improvement
A few participants recommended increasing the font size to improve label design; placing small bottles in a larger box was one suggestion: ''maybe you could put it [the bottle of Panadol suppositories] in a box with big writing on it'' (FG2 F2). One participant preferred to have the active ingredient in larger font. Another recognized a potential to more effectively utilize the total packaging space to include more relevant content (such as contraindications) ( 
Consumer Perspectives on Existing and Proposed OTC Labeling Standardization Strategies
Participants from every focus group were positive toward OTC label standardization. Standardization of OTC labels (both Drug Facts label and MIB) was positively supported by most participants, with many having a more positive disposition toward the Drug Facts label in comparison to existing Australian OTC labels. Many appeared to prefer the Drug Facts label compared to the MIB, explicitly identifying that, first, it was more helpful because of reference to additional information sources such as websites and telephone numbers, allowing people to seek information beyond the label; and second, the use of additional, descriptive subheadings (corresponding to the action required to be taken) in the Drug Facts label, which helped divide the large ''Warnings'' section.
Conversely, some MIB aspects were appreciated and seen as favorable over the Drug Facts label, such as tabulated dosage and slightly clearer headings. A few did not indicate a preference, where both formats were seen as comparable regarding perceived ease of use.
Consumer perspectives on the Drug Facts label
Positive perspectives. Participants reported that the Drug Facts label had a good or clear layout, which was indicated in every focus group. It was seen as easy to navigate, and able to promote increased ease of OTC product selection. Effective subheadings helped break up larger sections such as the ''Warnings.'' A few thought that the Drug Facts label was ''perfect.'' The black-and-white format exhibited by most labels contributed to their clarity.
Participants found the inclusion of a telephone number or helpline helpful. The inclusion of both active and inactive ingredients was liked ( Table 4 , quote 8).
Inclusion of inactive ingredient information provided reassurance that manufacturers were not withholding information. The communication of active ingredient together with its purpose was seen to give meaning to the active ingredient.
Negative perspectives. There were very few negatives raised by participants regarding the Drug Facts label. One participant implied that there was insufficient information regarding drug interactions, where ''you would still have to jump on the Internet or ask the pharmacist to get that information'' (FG2 M2).
Consumer perspectives on the MIB
The MIB was appreciated for its bullet points, clear headings, ample white space, and plain English use.
Some liked the black-and-white format. A few participants noted that the headings stood out more clearly, compared to the Drug Facts label. Specifically, pholcodine dosage tabulation was liked (raised in each of the focus groups) and seen to help support accurate retrieval of pholcodine dosage information ( Table 4 , quote 9). However, a small number of consumers did not like the tabulated directions in the diclofenac MIB. Participants identified areas for improvement, broadly regarding MIB content and title. Although content coverage was considered good, participants identified discrepancies between the Drug Facts label and MIB content. One participant felt that the MIB was not sufficiently informative. Absence of inactive ingredient information, manufacturer information (website and/or emergency contact information), and lack of active ingredient conveyed side by side with the ''purpose'' were identified as MIB shortcomings, which could then be inherently and/or directly linked in many cases to perceived necessary improvements.
One participant raised the issue that despite the warning to avoid use if allergic to any of the ingredients, the lack of inactive ingredient information in the MIB meant they could not satisfactorily discern if allergies were applicable.
Participants compared the 2 titles used for the standardized label formats and proposed possible variations to the title ''Medicine Information Box.'' They preferred the term ''medicine'' over ''drug.'' However, the Drug Facts title was favored by one participant, as '' 'Drug Facts' is better because it sort of conveys the gravity of it a little bit more than 'medicine' '' (FG2 F3).
Others suggested Medicine Facts as a potential title, regarded as ''a good blend of seriousness but not using the word 'drugs''' (FG2 M2). In addition, one participant assumed that in Australia, ''we preferentially used 'information' rather than 'facts' because it's less prescriptive and . . . there isn't as much weight behind information. Like not saying that it's a fact; you're just giving us information in you know good umm good . . . faith'' (FG3 M4). Omission of the word ''box'' in ''Medicine Information Box'' was also proposed.
Discussion
This is the first study that has evaluated Australian consumer opinions on current Australian OTC labels, the proposed standardized OTC label format for Australia, and US standardized Drug Facts labels. The evaluation was qualitative and exploratory in nature, and has identified consumer preferences as well as recommendations to inform the standardization of OTC labeling in Australia. Participants on the whole preferred the Drug Facts label over the existing Australian OTC labels and MIB. tiny writing, not easy to read. I mean I really would have picked this up by accident so. . . . '' (FG2 F2) 4. ''You see for me that's different. That one [Nurofen label] for me is harder to read just because I have eye problems, whereas this one where it's clearly darker blue and the yellow-that's easier for me to read. Umm everyone is different but that's just me.'' (FG2 F4) Label content-perceptions and identified discrepancies 5. ''The thing I noticed is that this one on the box doesn't have anything about the poisons [centre] or what to call, but it has it in here [in the leaflet], so if someone goes and throws that out and it's not on the box and they can't use the Internet. . . . '' (FG2 F2) 6. ''There's not much information on the [Daktarin] box as such so you really do need to take out the brochure and the brochure is really good because it has lots of clear subheadings . . . one of the sub headings is umm why not to use it and it's if you're pregnant. And I'm thinking why isn't it on the outside of the box? You wouldn't think athlete's foot cream would annoy a pregnancy but it obviously does and I think that's really important, that it's just not there.'' (FG3 F2) Suggestions for label design improvement 7. ''Umm yeah they, they could have done less of the blue and more you know ''Don't use if'' umm before I have to drag this [leaflet] out in the supermarket. It's not that easy to start reading pamphlets in the supermarket because you're always in a hurry to get home.'' (FG3 F2) Despite the MIB being modeled on the Drug Facts label, 15 all aspects of the Drug Facts label appear not to have been fully adopted. Many MIB shortcomings identified by participants were in fact the preferred characteristics seen on the Drug Facts label. This, therefore, brings to the forefront the notion of whether the MIB would constitute an overall improvement over the existing Drug Facts standardized OTC label format that participants preferred. The observed preference for the Drug Facts label, also supported by previous work, 7 indicates that the MIB should incorporate more aspects of the Drug Facts label to better cater to consumers' reported needs. Interestingly, the Australian TGA released a follow-up consultation in August 2014 (after completion of this study), proposing a revised version of the MIB. 20 This revised format shares more similarities to the Drug Facts label 6 in comparison to the original proposed MIB, 15 such as the structure of the ''Warnings'' section and the inclusion of the ''Other information'' heading. However, the present study highlights some potential improvements that still remain unaddressed.
Inclusion of additional information sources, inactive ingredients, contact details, and the colocation of the active ingredient(s) and its purpose were key reported differences between the Drug Facts label and MIB. Participants preferred the Drug Facts label over the MIB, as it included content on additional information sources. Consumers do not solely rely on the label for all their OTC medicine information needs, 2 and both receive 1 and utilize 21 a variety of information sources in the context of self-management. Consumers have also previously noted that labels alone are unable to completely support safe OTC medicine use as a stand-alone information source. 22 Further contact information should therefore be included in the MIB in future.
More comprehensive inactive ingredient information inclusion in the MIB should also be considered and taken forward, similar to the conclusion of an older US study published prior to the implementation of the Drug Facts label. 23 However, a potential barrier, from a regulatory perspective within the Australian context, is that complete inactive ingredient information on Australian OTC labels is currently not legislated; only specific inactive ingredients, such as ethanol and lactose, are mandated for inclusion. 13 Participants liked the active ingredient(s) presented alongside its purpose. Consumer focus on OTC medicine benefits 24 and the opportunity for information contextualization may explain why linking the two through effective information design is of particular importance. Consequently, adoption of this strategy in the MIB should be considered as a step to promoting safe and quality use of OTC medicines.
Existing diversity among Australian OTC packaging contributed to variations in perceived quality in the present study, where OTC label content diversity has also been previously identified. 25,26 Despite many participants indicating an overall preference for the Drug Facts label, aspects of existing Australian OTC labels and the MIB were still considered as positive. This reflected good information design principles advocated for use in written medicine information 27 and were comparable to the findings of semistructured interviews previously conducted with Australian and UK participants. 16 When comparing these study findings to the semistructured interviews, 16 participants in the group discussions focused more on identifying content discrepancies demonstrated by the MIB and on suggesting alternative titles for the MIB. This may be due to differences in stimulus material provided to participants between the 2 studies (one existing OTC label and a corresponding mock MIB label provided in the semistructured interviews 16 ; various OTC label formats provided in the present study), affecting the scope of discussion. Additionally, negative emotional responses to the MIB, mentioned in the semistructured interviews, 16 were not raised in this study. This may be due in part to the black-and-white Drug Facts labels available as comparators, which may have been less daunting when presented as part of complete packaging, with color used on other panels on those packs. Consequently, future work should explore consumer opinions of alternative MIB versions, with the MIB revised in light of these study findings, as part of complete packaging to provide context for consumers. The aim should be to develop better performing labels that take into consideration characteristics relevant to both preferences and results from evaluations by consumers. 28 In addition, efforts should ensure that packaging size does not become a rate-limiting factor influencing OTC label content and design, and their ability to support safe medication use.
As OTC label standardization is currently implemented in the United States, regulatory bodies such as the Australian TGA should learn from the impact of the Drug Facts label; however, proposals put forward must remain within the Australian context. Presently, there is insufficient evidence to support the implementation of either the Drug Facts label or the MIB in an Australian context or that this strategy would be advantageous from a label usability standpoint. As this study did not aim to investigate the usability of the MIB or the Drug Facts label formats using diagnostic performance testing with consumers, 29 future research should apply the recommendations and user test standardized OTC labels to ensure that implemented labels are fit for purpose.
When examining research conducted in relation to the Drug Facts label, while evidence suggests that it was an improvement on label formats available around the time of its proposal, some evaluations 8, 9 were conducted after its introduction. Unsurprisingly, issues pertinent to potentially reduced OTC label quality still exist after implementation of the Drug Facts label, 30, 31 highlighting the critical role of post-implementation evaluation, in conjunction with thorough pre-implementation needs analysis and performance testing. OTC label standardization in Australia must be implemented alongside an audit process to ensure ongoing monitoring, thereby enabling opportunities for timely optimization where necessary. Similarly, the positive impact of a US campaign that yielded an increased use of medicine information included on OTC labels, with more than half being knowledgeable of the Drug Facts label 1 year after widespread implementation, 32 indicates the potential importance of a similar, timely campaign in Australia if standardization is implemented.
Certain limitations of the present study should be acknowledged. The MIBs were presented to participants as paper copies, rather than incorporated as part of complete OTC packaging. This was due to the exploratory nature of the study, and as the MIB has not been implemented. Accordingly, this distinction among stimulus materials may have affected participant opinions of the MIB.
Conclusions
Participants appreciated characteristics of existing Australian OTC labels, Drug Facts, and MIB label formats that contributed to perceived usability and format clarity. However, many implied a broad preference for the Drug Facts label, partly because of its increased perceived completeness. The absence of inactive ingredient information, contact details, and parallel communication of the active ingredient and its purpose were identified as gaps in the MIB labels. Consideration should be given to incorporating these aspects into the MIB. Performance testing of the resultant improved label format with consumers is a key necessary next step to demonstrate the extent to which the format supports both perceived and actual OTC label quality and usability.
